Addressing the HIV Treatment Gap

• Current therapeutics (cART) only serve to control the HIV viral load and do not address the latent infection which will rebound if cART is discontinued.
  
  
• Future treatments must prioritize reducing or eliminating the latent reservoir of HIV-infected cells to effectively halt disease progression or transmission.
  
  
• SHC Therapeutics is positioned to bring the first effective latent reservoir eliminator to patients through its discovery of the precision immunotherapeutic, HIV-Like Particle (HLP)